Live
- Prabhas Donates Rs 35 Lakh to Support Telugu Film Directors Association
- Rashmika Mandanna Joins Dhanush and Nagarjuna in the Shoot for 'Kubera’
- Alliance Victory in Tanuku Constituency Marks Turning Point for Development," TDP
- YSRCP Minister Viddala Rajini Promises Development in Guntur West
- Mahesh Babu’s AMB Cinemas set to open in Bangalore
- YSRCP MP candidate Vijayasai Reddy assures protection of Muslim interests
- Vishwak Sen completes dubbing for ‘Gangs of Godavari’ teaser
- Tamannaah summoned by Maharashtra Cyber Cell over alleged Fairplay betting app involvement
- CM Jagan Files Nomination in Pulivendula Amidst Enthusiastic Support
- YSRCP MLA Candidate Mekapati Vikram Reddy Files Nomination for Atmakur Constituency
Aurobindo plant gets relief from USFDA
Aurobindo Pharma on Tuesday said the US health regulator has decided that the inspection classification of company's injectable formulation manufacturing facility at Hyderabad is voluntary action indicated (VAI)
Hyderabad: Aurobindo Pharma on Tuesday said the US health regulator has decided that the inspection classification of company's injectable formulation manufacturing facility at Hyderabad is voluntary action indicated (VAI).
As per the USFDA, a VAI inspection classification indicates that although investigators found and documented objectionable conditions during the inspection, FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time.
The inspection of Unit IV at Hyderabad, an injectable manufacturing formulation facility of the company, was conducted between November 4-13, 2019 by the United States Food and Drug Administration (USFDA), Aurobindo Pharma said.
"The USFDA has determined that the inspection classification of this facility is VAI," it added.
